The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial

ConclusionsIn patients with AS, IV golimumab produced sustained improvements in HRQoL and productivity through 1  year, which correlated with improvements in disease activity and functioning.ClinicalTrials.gov registry number is NCT02186873.Key Points•Intravenous (IV) golimumab resulted in clinically important improvement in general and ankylosing spondylitis-specific health-related quality of life (HRQoL) and productivity outcomes in patients with ankylosing spondylitis (AS) as early as week 8 and maintained improvement through 1  year•Improvements in HRQoL and productivity outcomes in these patients with AS were correlated with improvements in measures of disease activity and patient functional capability•IV golimumab is an effective treatment option for AS that can help mitigate the negative effects of the disease on HRQoL and productivity
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research